Cancer Vaccines & Circulating Tumor Cells (CTCs) 2011 Report
This market report from Select Biosciences presents a comprehensive industry analysis of the cancer vaccines space as well as that of the emerging circulating tumor cells (CTCs) space. These two areas are evolving and expanding driven by the greater emphasis on personalized medicine especially in the cancer/oncology space.
Cancer vaccines can be generated using a number of different approaches and this report describes these approaches vis-à-vis their advantages and disadvantages and associated technical characteristics. Indeed, the FDA-approval of a cancer vaccine for prostate cancer in 2010 was a key milestone in this space and a driver for R&D efforts forward. This report presents the pre-clinical pipeline, early-stage clinical trial pipeline, and the late-stage clinical pipeline for the cancer vaccines space. Also presented are the failed vaccine candidates with a discussion about these failures and how the industry can benefit via a deeper understanding of what components are required for effective immune system activation in vivo and effective vaccination—either preventative or therapeutic.
This report also examines the technology and market landscape for circulating tumor cells (CTCs). There is currently much interest in CTCs as they may offer a highly-sensitive biomarker for cancer detection via a minimally-invasive route. The cancer research field is currently seeking to understand the role of CTCs in metastases and in this vein this report is highly-useful in that it frames the biology of CTCs, characteristics of CTCs, methodologies for CTC enrichment, CTC detection, and analytical methods. This report also snapshots the clinical trials being conducted currently involving CTCs.
Extensive Worldwide Technical and Market Analyses Presented in this Report:
Cancer vaccines can be generated using a number of different approaches and this report describes these approaches vis-à-vis their advantages and disadvantages and associated technical characteristics. Indeed, the FDA-approval of a cancer vaccine for prostate cancer in 2010 was a key milestone in this space and a driver for R&D efforts forward. This report presents the pre-clinical pipeline, early-stage clinical trial pipeline, and the late-stage clinical pipeline for the cancer vaccines space. Also presented are the failed vaccine candidates with a discussion about these failures and how the industry can benefit via a deeper understanding of what components are required for effective immune system activation in vivo and effective vaccination—either preventative or therapeutic.
This report also examines the technology and market landscape for circulating tumor cells (CTCs). There is currently much interest in CTCs as they may offer a highly-sensitive biomarker for cancer detection via a minimally-invasive route. The cancer research field is currently seeking to understand the role of CTCs in metastases and in this vein this report is highly-useful in that it frames the biology of CTCs, characteristics of CTCs, methodologies for CTC enrichment, CTC detection, and analytical methods. This report also snapshots the clinical trials being conducted currently involving CTCs.
Extensive Worldwide Technical and Market Analyses Presented in this Report:
- Classification and Characterization of Cancer Vaccines
- Various Approaches for the Generation of Cancer Vaccines
- Anti-Cancer Vaccination Strategies
- Tumor Associated Antigens (TAAs)
- Tumor Specific Antigens (TSAs)
- Failed Anti-Cancer Vaccine Candidates and Reasons for such Failure
- Strategies to Improve Success of Cancer Vaccines
- US FDA-Approved Cancer Vaccines
- Therapeutic Cancer Vaccines Approved in Various Countries Around the World
- Cancer Vaccine Pipeline in Late-Stage Clinical Trials
- Cancer Vaccine Pipeline in Early-Stage Clinical Trials
- Pre-Clinical Cancer Vaccine Pipeline
- Personalized Cancer Vaccination Strategies
- Biology and Characteristics of CTCs
- Methodologies/Various Technologies for Enrichment, Detection, and Characterization of CTCs
- More details of the scope of coverage of this industry report are found in the Table of Contents (TOC) for the report—see below for link to downloadable PDF of the TOC
CHAPTER I. EXECUTIVE OVERVIEW
CHAPTER II. CANCER VACCINES: TECHNOLOGY & MARKET ANALYSIS
Cancer Immunotherapy Overview
Historical Milestones in Cancer Immunotherapy
Classification of Cancer Vaccines
Tumor Associated Antigens (TAAs)
Tumor Specific Antigens (TSAs)
Anti-Cancer Vaccination Strategies
Failed Therapeutic Cancer Vaccine Candidates
Strategies to Improve Success of Cancer Vaccines
Cancer Vaccines Market Overview
US FDA-Approved Cancer Vaccines: Preventative & Therapeutic
Therapeutic Cancer Vaccines Approved in Various Countries
Cancer Vaccine Pipeline in Phase III Clinical Trials
Early Stage (Phases I & II) Pipeline
Pre-Clinical Pipeline
Personalized Vaccines
CHAPTER III. CIRCULATING TUMOR CELLS (CTCS): TECHNOLOGY & MARKET ANALYSIS
Metastasis and Epithelial-to-Mesenchymal Transition (EMT)
What are CTCs?
CTCs vs. DTCs
Clinical Relevance of CTCs
Characteristics of CTCs
Detection and Diagnostics of CTCs
Biology of CTCs
CTC Analysis Methodologies
CTC Enrichment, Detection, and Characterization Methods
Microfluidic Devices for CTC Detection
Clinical Trials Involving CTC Analysis
APPENDIX I. RESEARCH METHODOLOGY
CHAPTER II. CANCER VACCINES: TECHNOLOGY & MARKET ANALYSIS
Cancer Immunotherapy Overview
Historical Milestones in Cancer Immunotherapy
Classification of Cancer Vaccines
Tumor Associated Antigens (TAAs)
Tumor Specific Antigens (TSAs)
Anti-Cancer Vaccination Strategies
Failed Therapeutic Cancer Vaccine Candidates
Strategies to Improve Success of Cancer Vaccines
Cancer Vaccines Market Overview
US FDA-Approved Cancer Vaccines: Preventative & Therapeutic
Therapeutic Cancer Vaccines Approved in Various Countries
Cancer Vaccine Pipeline in Phase III Clinical Trials
Early Stage (Phases I & II) Pipeline
Pre-Clinical Pipeline
Personalized Vaccines
CHAPTER III. CIRCULATING TUMOR CELLS (CTCS): TECHNOLOGY & MARKET ANALYSIS
Metastasis and Epithelial-to-Mesenchymal Transition (EMT)
What are CTCs?
CTCs vs. DTCs
Clinical Relevance of CTCs
Characteristics of CTCs
Detection and Diagnostics of CTCs
Biology of CTCs
CTC Analysis Methodologies
CTC Enrichment, Detection, and Characterization Methods
Microfluidic Devices for CTC Detection
Clinical Trials Involving CTC Analysis
APPENDIX I. RESEARCH METHODOLOGY
